Tag: acquisition

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Zillow (Z) To Contact Him Directly To Discuss Their Options

New York, NY, June 10, 2026 (GLOBE NEWSWIRE) -- byNordic Acquisition Corporation (“BYNO” or the “Company”), a special purpose acquisition company, announced today that the Company has timely deposited into the Company’s trust account (the “Trust Account”), an aggregate of $17,470, in order to extend the period of time the Company has to complete a business combination for an additional one (1) month period, from June 12, 2026 to July 12, 2026 (the “Extension”). The Extension is the eleventh of up to twelve (12) one-month extensions permitted under the August 8, 2025 amendment to the Company’s Amended and Restated Certificate of Incorporation that allows the Company’s board of directors, in its sole discretion and without another stockholder vote, to elect to extend the termination date by one additional month each time up until August 12, 2026, or the closing of the Company’s initial business combination.

LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva’s acquisition of Emalex Biosciences, strengthening its late-stage pipeline with ecopipam and further advancing its Pivot to Growth strategy. Phase 3 data for ecopipam were recently published in JAMA Neurology, and a U.S. NDA submission is anticipated in the second half of 2026. 

AB Pieno Zvaigzdes has received a notification from the persons discharging managerial responsibilities regarding the transactions in the Company's securities (enclosed).

As previously announced today in a press release, Ascencio (the “Company”) has launched a capital increase in cash within the limits of the authorised capital via an accelerated bookbuilding process mainly with qualified investors, with a waiver of the preferential subscription rights of existing shareholders.